Shopping Cart
- Remove All
Your shopping cart is currently empty
BNT411, a selective TLR7 agonist, induces IFNα release both in vivo and in vitro. With anticancer activity, BNT411 is applicable in cancer research, including non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC) [1].

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $5,640 | 6-8 weeks | |
| 50 mg | $8,410 | 6-8 weeks | |
| 100 mg | $10,790 | 6-8 weeks |
| Description | BNT411, a selective TLR7 agonist, induces IFNα release both in vivo and in vitro. With anticancer activity, BNT411 is applicable in cancer research, including non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC) [1]. |
| In vivo | BNT411 (3 mg/kg; administered via intravenous injection every 4 to 5 days, for a total of 8 doses) demonstrates antitumor activity in a mouse tumor model [1]. |
| Molecular Weight | 439.55 |
| Formula | C24H33N5O3 |
| Cas No. | 2296821-50-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.